Inhibition of tryptophan-dioxygenase activity increases the antitumor efficacy of immune checkpoint inhibitors
Tryptophan 2,3-dioxygenase (TDO) is an enzyme that degrades tryptophan into kynurenine and thereby induces immunosuppression. Like indoleamine 2,3-dioxygenase (IDO1), TDO is considered as a relevant drug target to improve the efficacy of cancer immunotherapy. However, its role in various immunothera...
Principais autores: | Schramme, F, Crosignani, S, Frederix, K, Hoffmann, D, Pilotte, L, Stroobant, V, Preillon, J, Driessens, G, Van Den Eynde, B |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
American Association for Cancer Research
2019
|
Registros relacionados
-
Tryptophan 2,3-dioxygenase expression identified in murine decidual stromal cells is not essential for feto-maternal tolerance
por: Hoffmann, D, et al.
Publicado em: (2020) -
Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance
por: Delia Hoffmann, et al.
Publicado em: (2020-12-01) -
Induction of tryptophan 2,3-dioxygenase expression in human monocytic leukemia/lymphoma cell lines THP-1 and U937
por: Hoffmann, D, et al.
Publicado em: (2019) -
Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase
por: Klaessens, S, et al.
Publicado em: (2021) -
Rational design of original fused-cycle selective inhibitors of tryptophan 2,3-dioxygenase
por: Kozlova, A, et al.
Publicado em: (2021)